Ecopipam: Ph IIb PSY302 data

Data from 40 Tourette’s patients ages 7-17 in the double-blind, U.S. Phase IIb PSY302 trial showed that once-daily oral ecopipam met the primary endpoint, leading to a mean 5 point reduction in YGTSS-TTS from baseline to 2 and 4 weeks vs. placebo. Ecopipam was well tolerated. Based on body weight, patients received 50 (n=4) or 100 mg ecopipam (n=36) or placebo for 4 weeks and crossed over to the other treatment for another 4 weeks.

The company plans to present final PSY302 data at the International Congress of Parkinson's Disease and Movement Disorders in Vancouver in June...